Logo image of VERO

VENUS CONCEPT INC (VERO) Stock Fundamental Analysis

NASDAQ:VERO - Nasdaq - US92332W2044 - Common Stock - Currency: USD

3.15  +2.87 (+1025%)

After market: 3.11 -0.04 (-1.27%)

Fundamental Rating

1

VERO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VERO have multiple concerns. VERO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VERO had negative earnings in the past year.
VERO had a negative operating cash flow in the past year.
VERO had negative earnings in each of the past 5 years.
In the past 5 years VERO always reported negative operating cash flow.
VERO Yearly Net Income VS EBIT VS OCF VS FCFVERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -69.38%, VERO is not doing good in the industry: 75.81% of the companies in the same industry are doing better.
VERO has a worse Return On Equity (-496.11%) than 88.17% of its industry peers.
Industry RankSector Rank
ROA -69.38%
ROE -496.11%
ROIC N/A
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VERO Yearly ROA, ROE, ROICVERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

VERO's Gross Margin of 67.68% is fine compared to the rest of the industry. VERO outperforms 74.19% of its industry peers.
VERO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for VERO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%
VERO Yearly Profit, Operating, Gross MarginsVERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VERO has more shares outstanding
VERO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VERO is higher compared to a year ago.
VERO Yearly Shares OutstandingVERO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
VERO Yearly Total Debt VS Total AssetsVERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.77, we must say that VERO is in the distress zone and has some risk of bankruptcy.
VERO has a worse Altman-Z score (-5.77) than 72.04% of its industry peers.
VERO has a Debt/Equity ratio of 3.40. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 3.40, VERO is doing worse than 87.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.4
Debt/FCF N/A
Altman-Z -5.77
ROIC/WACCN/A
WACC6.99%
VERO Yearly LT Debt VS Equity VS FCFVERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 1.86 indicates that VERO should not have too much problems paying its short term obligations.
VERO's Current ratio of 1.86 is on the low side compared to the rest of the industry. VERO is outperformed by 71.51% of its industry peers.
A Quick Ratio of 1.18 indicates that VERO should not have too much problems paying its short term obligations.
VERO has a Quick ratio of 1.18. This is in the lower half of the industry: VERO underperforms 70.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.18
VERO Yearly Current Assets VS Current LiabilitesVERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for VERO have decreased strongly by -15.56% in the last year.
Looking at the last year, VERO shows a very negative growth in Revenue. The Revenue has decreased by -18.57% in the last year.
VERO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.26% yearly.
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-14.81%

3.2 Future

Based on estimates for the next years, VERO will show a very strong growth in Earnings Per Share. The EPS will grow by 23.03% on average per year.
Based on estimates for the next years, VERO will show a decrease in Revenue. The Revenue will decrease by -2.58% on average per year.
EPS Next Y-1.78%
EPS Next 2Y32.73%
EPS Next 3Y23.03%
EPS Next 5YN/A
Revenue Next Year-18.14%
Revenue Next 2Y-7.31%
Revenue Next 3Y-2.58%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VERO Yearly Revenue VS EstimatesVERO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VERO Yearly EPS VS EstimatesVERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VERO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERO Price Earnings VS Forward Price EarningsVERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERO Per share dataVERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

VERO's earnings are expected to grow with 23.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.73%
EPS Next 3Y23.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VENUS CONCEPT INC

NASDAQ:VERO (3/4/2025, 5:43:26 PM)

After market: 3.11 -0.04 (-1.27%)

3.15

+2.87 (+1025%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-31 2025-03-31/amc
Inst Owners27.79%
Inst Owner Change-28.58%
Ins Owners1.96%
Ins Owner Change0%
Market Cap22.87M
Analysts45.71
Price TargetN/A
Short Float %0.01%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-56.48%
Min EPS beat(2)-108.38%
Max EPS beat(2)-4.58%
EPS beat(4)0
Avg EPS beat(4)-46.69%
Min EPS beat(4)-108.38%
Max EPS beat(4)-4.58%
EPS beat(8)2
Avg EPS beat(8)-20.68%
EPS beat(12)3
Avg EPS beat(12)-30.31%
EPS beat(16)4
Avg EPS beat(16)-25.37%
Revenue beat(2)0
Avg Revenue beat(2)-9.54%
Min Revenue beat(2)-14.85%
Max Revenue beat(2)-4.24%
Revenue beat(4)1
Avg Revenue beat(4)-9.35%
Min Revenue beat(4)-20.82%
Max Revenue beat(4)2.5%
Revenue beat(8)3
Avg Revenue beat(8)-4.34%
Revenue beat(12)4
Avg Revenue beat(12)-4.56%
Revenue beat(16)6
Avg Revenue beat(16)-3.48%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.36%
EPS NQ rev (3m)0.36%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)-1.22%
Revenue NQ rev (3m)-1.22%
Revenue NY rev (1m)-0.33%
Revenue NY rev (3m)-0.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 5.37
EV/EBITDA N/A
EPS(TTM)-8.02
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS9.26
BVpS1.39
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.38%
ROE -496.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.68%
FCFM N/A
ROA(3y)-29.74%
ROA(5y)-32.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y9.61%
F-Score3
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 3.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.73%
Cap/Sales 0.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.18
Altman-Z -5.77
F-Score3
WACC6.99%
ROIC/WACCN/A
Cap/Depr(3y)6.99%
Cap/Depr(5y)16.38%
Cap/Sales(3y)0.33%
Cap/Sales(5y)0.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.95%
EPS Next Y-1.78%
EPS Next 2Y32.73%
EPS Next 3Y23.03%
EPS Next 5YN/A
Revenue 1Y (TTM)-18.57%
Revenue growth 3Y-0.71%
Revenue growth 5Y28.26%
Sales Q2Q%-14.81%
Revenue Next Year-18.14%
Revenue Next 2Y-7.31%
Revenue Next 3Y-2.58%
Revenue Next 5YN/A
EBIT growth 1Y4.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.88%
EBIT Next 3Y24.68%
EBIT Next 5YN/A
FCF growth 1Y67.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.51%
OCF growth 3YN/A
OCF growth 5YN/A